Compare AXT Inc (AXTI) vs Summit Therapeutics Inc (SMMT) Price & Performance

AXTI trades at $78.47, up 6.31% on the day, with a bullish technical signal from moving averages and strong earnings beats in Q1 and Q2 2026. Revenue surged to $126 million in 2026 with a return to profitability, driven by record indium phosphide demand for AI data centers. The company secured a long-term supply agreement with Lumentum, accelerating capacity expansion.

Outlook is positive given AI-driven demand and analyst consensus, but high valuation ratios and operational cash flow deficits pose risks. The stock trades above the consensus price target of $72.50, suggesting near-term consolidation may occur before further gains.

Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.

The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.